Capricor Therapeutics (NASDAQ:CAPR) Price Target Raised to $30.00 at Cantor Fitzgerald

Capricor Therapeutics (NASDAQ:CAPR) had its price objective hoisted by stock analysts at Cantor Fitzgerald from $25.00 to $30.00 in a note issued to investors on Thursday,Benzinga reports. The firm currently has an “overweight” rating on the biotechnology company’s stock. Cantor Fitzgerald’s price objective indicates a potential upside of 77.41% from the company’s previous close.

Several other equities analysts have also issued reports on CAPR. Maxim Group boosted their target price on shares of Capricor Therapeutics from $12.00 to $25.00 and gave the company a “buy” rating in a report on Wednesday, September 25th. HC Wainwright restated a “buy” rating and set a $40.00 target price on shares of Capricor Therapeutics in a research report on Wednesday, October 9th. Piper Sandler assumed coverage on Capricor Therapeutics in a report on Monday, October 21st. They issued an “overweight” rating and a $35.00 target price for the company. Finally, Oppenheimer restated an “outperform” rating and set a $15.00 price target on shares of Capricor Therapeutics in a report on Monday, September 23rd. One equities research analyst has rated the stock with a sell rating and six have given a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $28.33.

Capricor Therapeutics Stock Performance

Capricor Therapeutics stock opened at $16.91 on Thursday. Capricor Therapeutics has a 52-week low of $2.80 and a 52-week high of $23.40. The firm has a 50 day moving average price of $14.63 and a two-hundred day moving average price of $8.29. The firm has a market cap of $767.88 million, a price-to-earnings ratio of -18.18 and a beta of 4.00.

Insider Buying and Selling at Capricor Therapeutics

In other news, major shareholder Shinyaku Co Ltd Nippon bought 2,798,507 shares of the stock in a transaction dated Friday, September 20th. The shares were bought at an average cost of $5.36 per share, with a total value of $14,999,997.52. Following the completion of the transaction, the insider now directly owns 7,090,351 shares of the company’s stock, valued at $38,004,281.36. This trade represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 12.00% of the company’s stock.

Hedge Funds Weigh In On Capricor Therapeutics

A number of hedge funds have recently bought and sold shares of CAPR. BNP Paribas Financial Markets bought a new position in shares of Capricor Therapeutics during the first quarter valued at about $40,000. Main Street Financial Solutions LLC increased its stake in Capricor Therapeutics by 37.5% in the 2nd quarter. Main Street Financial Solutions LLC now owns 27,500 shares of the biotechnology company’s stock valued at $131,000 after buying an additional 7,500 shares during the last quarter. SG Americas Securities LLC bought a new position in shares of Capricor Therapeutics during the 3rd quarter worth approximately $133,000. Rhumbline Advisers purchased a new position in shares of Capricor Therapeutics in the 2nd quarter worth approximately $147,000. Finally, The Manufacturers Life Insurance Company bought a new position in shares of Capricor Therapeutics in the third quarter valued at approximately $161,000. 21.68% of the stock is owned by hedge funds and other institutional investors.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.